

APPLYING NANOPARTICLES FOR TREATING *GIARDIA* INFECTION: A SYSTEMATIC REVIEW

HAMDAN I. ALMOHAMMED¹, AISHAH E. ALBALAWI², HADEEL AL SADOUN³, NAVID BAKHTIARI⁴, MORTEZA AMRAEI⁵, ALI MOGHADDAM⁶, GHAIJDA RAHEEM LATEEF AL-AWSI^{7*}

¹Department of Microbiology and Parasitology, Almaarefa University, Riyadh 11597, Saudi Arabia, ²Faculty of Science, University of Tabuk, Tabuk 47913, Saudi Arabia, ³Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia, ⁴Faculty of Pharmacy, Ayatollah Amoli Branch, Islamic Azad University, Amol, Iran, ⁵Department of Health Information Technology, School of Paramedical Sciences, Lorestan University of Medical Sciences, Lorestan, Khorramabad, Iran, ⁶Student Research Committee, Lorestan University of Medical Sciences, Khorramabad, Iran, ⁷Department of Radiological Techniques, Al-Mustaqbal University College, Babylon, Iraq
Email: ghaidaa.rahem@mustaqbal-college.edu.iq

Received: 18 Jun 2021, Revised and Accepted: 31 Jul 2021

ABSTRACT

At present, chemotherapy with some drugs such as nitroimidazoles derivatives is the preferred treatment for giardiasis. However, these agents are associated with adverse side effects ranging from nausea to possible genotoxicity. The present investigation was designed to systematically review the *in vitro*, *in vivo*, and clinical studies about the efficacy of nanoparticles against giardiasis. The study was carried out based on the 06-PRISMA guideline and registered in the CAMARADES-NC3Rs Preclinical Systematic Review and Meta-analysis Facility (SyRF) database. The search was performed in five English databases, including Scopus, PubMed, Web of Science, EMBASE, and Google Scholar, without time limitation for publications around the world about anti-*Giardia* effects of all organic and inorganic nanoparticles without date limitation in order to identify all the published articles. The searched words and terms were "Giardiasis", "*Giardia lamblia*", "*Giardia intestinalis*", "*Giardia duodenalis*", "nanoparticles", "nanomedicine", "*in vitro*", "*in vivo*", and "clinical trial". Out of 312 papers, 10 papers, including 4 *in vitro* (40.0%), 5 *in vivo* (50.0%), and 1 *in vitro/in vivo* (10.0%) up to 2021 met the inclusion criteria for discussion in this systematic review. The most common type of nanoparticles was metal nanoparticles (5 studies, 50.0%) such as silver, gold, etc., followed by organic nanoparticles such as chitosan nanoparticles (4 studies, 40.0%). The results of this review study showed the high efficacy of a wide range of organic and non-organic NPs against giardiasis, indicating that nanoparticles could be considered as an alternative and complementary resource for treating giardiasis, since they have no significant toxicity. However, more studies are required to elucidate this conclusion, especially in clinical systems.

Keywords: *Giardia lamblia*, *Giardia intestinalis*, *Giardia duodenalis*, Nanoparticles, Nanomedicine, *In vitro*, *In vivo*, Clinical trial

© 2021 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open-access article under the CC BY license (<https://creativecommons.org/licenses/by/4.0/>) DOI: <https://dx.doi.org/10.22159/ijap.2021v13i5.42466>. Journal homepage: <https://innovareacademics.in/journals/index.php/ijap>

INTRODUCTION

Giardia lamblia (syn. *Giardia intestinalis*, *Giardia duodenalis*) is a flagellated protozoan parasite that commonly causes giardiasis or acute and watery diarrhea [1]. The disease is considered as one of the main waterborne and foodborne diarrhea around the world, which infects about 280 million people annually [2]. Humans are generally infected through ingesting contaminated water and food, as well as person-to-person transmission. The most people at risk for giardiasis are children in day-care settings, child-care workers, institutionalized individuals, and travelers in endemic areas via ingestion of contaminated or recreational water, immunodeficiency, cystic fibrosis, and oral-anal sex [2, 3]. Although the disease is mostly asymptomatic, a number of clinical symptoms such as diarrhoea, steatorrhea, nausea, abdominal pain, vomiting, and weight loss are presented in the infected children [4].

At present, chemotherapy with some drugs such as metronidazole (MTZ), tinidazole, and nitazoxanide is the preferred treatment for giardiasis [5]. However, according to recent reports, these agents are associated with adverse side effects ranging from nausea and metallic taste in the mouth to psychosis, carcinogenesis, and possible genotoxicity [6]. In recent years, an alarming increase in resistance to the conventional agents with nitroimidazoles such as MTZ has been reported in various parts of the world. However, the promising strategies for this drug treatment failure are monotherapy with some effective drugs such as quinacrine as well as combined therapy with some agents [7]. Consequently, it is necessary to find new alternatives with high efficacy and low toxicity for treating giardiasis.

Over the last years, nanotechnology has been introduced as a relatively new field of science and technology that deals with nanometer-sized material for medical purposes [8]. This innovative technology has been used in various fields of sciences through a

combined approach. Nowadays, an increasing number of applications and products containing nanomaterials have been considered [8].

Use of nanotechnology for medical purposes has been named nanomedicine and is described as applying nanomaterials for diagnosis, monitoring, control, prevention, and treatment of diseases [9]. Although a wide range of *in vitro*, *in vivo*, and clinical studies have reported the antimicrobial effects of some inorganic nanoparticles (such as metal and metal oxide) and organic nanoparticles (peptide- and polymer-based nanoparticles such as cationic peptides, synthetic cationic polymers, chitosan, etc.) [10, 11]; but there is no documented report on the drug resistance of microbes, especially parasites, to nanoparticles. However, broad adoption of nanoparticles for giardiasis is at present hampered by uncertain findings of the investigation, not always sufficiently powered. Our study aimed to systematically review the existing literature (*in vitro* and *in vivo*) in the field of nanomedicine for giardiasis treatment.

MATERIALS AND METHODS

Search strategy

The current study was carried out using 06-PRISMA guideline and registered in the CAMARADES-NC3Rs Preclinical Systematic Review and Meta-analysis Facility (SyRF) database [12]. The search was performed in five English databases, including Scopus, PubMed, Web of Science, EMBASE, and Google Scholar without time limitation for publications worldwide related to anti-*Giardia* effects of organic and inorganic nanoparticles without date limitation in order to identify all the published articles (*in vitro*, *in vivo*, and clinical studies). Studies in any language were entered into the search step if they had an English abstract. The words and terms were used as a syntax with specific tags of each database. The searched words and terms were: "Giardiasis", "*Giardia lamblia*", "*Giardia intestinalis*", "*Giardia duodenalis*", "Nanoparticles", "Nanomedicine", "*In vitro*", and "*In vivo*" (fig. 1.).




Fig. 1: Flowchart describing the study design process

Quality assessment and article selection

First, the studies were imported to EndNote X9 software (Thomson Reuters, New York, NY, USA) and duplicate studies were deleted. Afterwards, three independent authors examined the title and abstract of the studies and the relevant studies were included for further analysis. The same authors carefully read the studies and the eligible studies with adequate inclusion criteria were selected.

Exclusion criteria

The studies with inadequate information, abstracts submitted in congresses without full texts, failure to match methods with results, and the incorrect interpretation of the results was excluded from the current study.

Inclusion criteria

Inclusion criteria of this study were the articles evaluating the effects of nanoparticles on giardiasis, emphasizing the design of various forms of nanoparticles containing drugs and other pharmaceutical formulations against giardiasis.

Data extraction

Three independent authors extracted information from the selected articles and, if needed, the differences were resolved by the corresponding author. The extracted data included nanoparticle type, in combination or loaded with other drugs, type of study, parasite form, condition, concentration, time of used and obtained findings, and references.

RESULTS AND DISCUSSION

Out of 312 papers, 10 papers including 4 *in vitro* (40.0%), 5 *in vivo* (50.0%), and 1 *in vitro/in vivo* (10.0%) up to 2021 met the inclusion criteria for discussion in this systematic review with the data extracted, as presented in table 1. The most common type of nanoparticles was metal nanoparticles (5 studies, 50.0%) such as silver, gold, etc., followed by and organic nanoparticles such as chitosan nanoparticles (4 studies, 40.0%). In this study, we investigated the effect of different nanoparticles on *Giardia* parasite and giardiasis disease, put the obtained information in a table, and categorized it. According to the nanoparticles mentioned in the table, we classified them into two categories of organic and inorganic nanoparticles and explained their effect on *Giardia*.

Organic nanoparticles

Chitosan

Chitosan (poly-(b-1/4)-2-amino-2-deoxy-D-glucopyranos) and its derivatives due to having some exceptional properties such as minimum toxicity, biocompatibility, and biodegradability, have been broadly used as an immunomodulatory, anticancer, anti-nociceptive, antioxidant, anti-inflammatory, and antimicrobial agent [23-26]. Today, it has been proven that chitosan-based biomedical drugs such as nanoparticles, hydrogels, coatings, suspensions, powders, membranes, films, etc. are able to affect the pharmaceutical and biomedical effects of these agents [27, 28]. In recent years, several studies have reported the antimicrobial effects of chitosan and its derivatives against a broad spectrum of pathogenic viruses, bacteria, fungi, as well as helminthic and protozoan parasites [29-31]. Yarahmadi *et al.* (2016) demonstrated the considerable chitosan nanoparticles (CNPs) synthesized by *Penicillium viridicatum* and *P. aurantiogriseum* at the doses of 50, 100, 200, and 400 µg/ml on *Giardia* cysts, whereas CNPs at the dose of 400 µg/ml and after 180 min exposure killed 100% *Giardia* cysts [13].

In addition, Chabra *et al.* (2019) reported that chitosan and nano-chitosan at the concentrations of 100, 200, and 400 µg/ml significantly reduced the *G. lamblia* trophozoite, ranging from 89 to 100, after 3 h exposure *in vitro*. The findings also showed that the oral administration of chitosan and nano-chitosan at the dose of 100 µg/kg significantly reduced the mean percentage of excreted cysts up to 10 times in the infected BALB/C mice *G. lamblia* [14].

In the study conducted by Elmi *et al.* (2020), CNPs synthesized by *Penicillium* fungi at the dose of 50 µg/ml after 180 min exposure eliminated 31.3% of *G. lamblia* cysts [19]. Said *et al.* (2012) also showed that synthesized CNPs prepared by ionic crosslinking of chitosan solution at the dose of 5 ppm for 8 d significantly reduced the number of *Giardia* cysts in the stool and trophozoites in intestinal sections of rats with giardiasis [16].

Recently, El-Gendy *et al.* (2021) demonstrated that oral administration of CNPs at the dose of 50µg/hamster/day for 7 consecutive days alone and especially in combination with MTZ in Syrian hamsters infected with *G. lamblia* significantly reduced the cysts and trophozoites counts by 63.64-94.69%. They also reported significant healing of intestinal mucosa in the infected hamsters after treatment with MTZ+CsNPs [15].

Table 1: A list of studies on effects of nanoparticles against giardiasis

Nanoparticle	Preparation method	Condition	Parasite form	Dose	Time	Outcome	Ref
Chitosan nanoparticles	-	<i>In vitro</i>	Cysts	50, 100, 200 and 400 µg/ml	10, 30, 60 and 180 min	CNPs synthesized by <i>Penicillium viridicatum</i> and <i>P. aurantiogriseum</i> at the doses of 50, 100, 200, and 400 µg/ml on <i>Giardia</i> cysts; whereas CNPs at the dose of 400 µg/ml and after 180 min exposure killed 100% <i>Giardia</i> cysts	[13]
Chitosan and nano-chitosan	Ionic gelation method -	<i>In vitro</i> <i>In vivo</i> (BALB/c mice)	Cysts and trophozoites	100, 200, 400 µg/ml And 10, 50, 100 µg/kg	30, 60, 180 Min and 24, 48, 72 h	Chitosan and nano-chitosan at the concentrations of 100, 200, and 400 µg/ml significantly reduced the <i>G. lamblia</i> trophozoite ranging from 89 to 100 after 3 h exposure <i>in vitro</i> ; they findings also showed that the oral administration of chitosan and nano-chitosan at the dose of 100 µg/kg significantly reduced the mean percentage of excreted cysts up to 10 times in infected BALB/C mice <i>G. lamblia</i>	[14]
Chitosan nanoparticles (CNPs)	Ionic gelation technique -	<i>In vivo</i> (Syrian hamsters)	Cysts and trophozoites	50 µg/hamster/day	7 d	CNPs, especially in combination with metronidazole (MTZ) significantly reduced the cysts and trophozoites counts from 63.64-94.69%. Histopathological tests demonstrated significant healing of intestinal mucosa after treatment with MTZ+CsNPs.	[15]
Chitosan nanoparticles	Ionic cross-linking and spontaneous emulsification method	<i>In vivo</i> (Rats)	Cysts	5 ppm	8 d	CNPs significantly reduced the cysts and trophozoites counts up to 68.2 and 79.6% in rats infected with <i>G. lamblia</i> , respectively.	[16]
Curcumin nanoparticles	Ionic cross-linking and spontaneous emulsification method	<i>In vivo</i> (Rats)	Cysts	450 mg	8 d	CNPs significantly reduced the cysts and trophozoites counts up to 54.6 and 51.7% in rats infected with <i>G. lamblia</i> , respectively.	[16]
Gold Nanoparticles (AuNPs)	-	<i>In vitro</i>	Cysts	0.05, 0.1, 0.3 mg/ml	5, 15, 30, 60 and 180 min	In this study, AuNPs were used <i>in vitro</i> on <i>Giardia</i> cysts isolated from stools. The results showed that the lethal effect of these nanoparticles with a concentration of 0.3 mg/ml in 5 min is 62% and in 180 min it reaches 96%. For this reason, it can be said that AuNPs at a concentration of 0.3 mg/ml have a lethal effect similar to metronidazole.	[17]
Gold nanoparticles and <i>Citrullus colocynthis</i> L. nanoparticles (nAu+nCc)	Green synthesis	<i>In vivo</i> (Swiss Albino Mice)	-	20 µg	8 d	In this study, the effect of combination therapy of nAu+nCc in the animal model was investigated. Experiments were performed on 50 Swiss Albino Mice infected with <i>Giardia</i> cysts using a nasogastric tube, and the results showed that combination therapy eliminated 93.2% of <i>Giardia</i> trophozoites.	[18]
Nano-chitosan	Ionotropic gelation method	<i>In vitro</i>	Cysts	1, 5, 10, 20, 40 and 50 µg/ml	180 min	In this study, Nano-chitosan obtained from <i>Penicillium waksmanii</i> , <i>P. aurantiogriseum</i> , <i>P. viridicatum</i> and <i>P. citrinum</i> were used. The results show that the greatest effect of these nanoparticles is at a concentration of 50 µg/ml, which has a lethal effect of 31.3%, and in addition, it was found that Nano-chitosan has little toxicity and side effects.	[19]
Selenium and Copper Oxide Nanoparticles (CuO NPs and Se NPs)	Purchased	<i>In vitro</i>	Cysts	0.15, 0.3, and 0.6 mg/ml	10, 15, 30, 60, and 180 min	In this study, the effect of CuO NPs and Se NPs with a size of 10 to 45 nm on <i>Giardia deudenalis</i> cysts obtained from patients' stools was investigated. The results showed that CuO NPs at a concentration of 0.6 mg/ml and Se NPs at a concentration of 0.3 mg/ml had a similar effect to metronidazole on cysts.	[20]
Silver nanoparticles (Ag NPs)	Purchased	<i>In vivo</i> (BALB/c mice)	-	100 µg/g	24, 48 and 72 h	In this study, the anti- <i>Giardia</i> ability of Ag NPs as a combination therapy with metronidazole and alone was investigated. Experiments showed that in 72 h of combined treatment of Ag NPs and metronidazole has an effect of 83.30% and the use of nanoparticles alone has the same effect. But in 24 h the effect of Ag NPs is 66.60%, which is greater than the effect of metronidazole.	[21]
Silver nanoparticles	Ionic cross-linking and spontaneous emulsification method and green synthesis	<i>In vivo</i> (Rats)	Cysts	100 ppm	8 d	CNPs significantly reduced the <i>Giardia</i> cysts and trophozoites counts up to 72.7 and 81.1% in rats infected with <i>G. lamblia</i>	[16]
Zinc oxide nanoparticles (ZnO-NPs)	Purchased	<i>In vivo</i> (BALB/c mice)	-	10 mg/kg	7 d	In this study, we investigated the effect of ZnO-NPs and metronidazole on <i>Giardia intestinalis</i> -infected mice. Studies have shown that ZnO-NPs in the mentioned dose can kill 93.7% of cysts and also metronidazole in 500 mg/kg dose can kill 99.2% of cysts while combined treatment with both The drug has a 100% result.	[22]

Curcumin

Curcumin is a natural polyphenol compound derived from turmeric root with various pharmacological properties [32]. It has many therapeutic properties such as anti-inflammatory, anti-cancer, antioxidant, and antimicrobial activity. Considering the anti-parasitic activities of curcumin, reviews showed the potent efficacy of curcumin against some pathogenic species of *Plasmodium*, *Leishmania*, *Trypanosoma*, *Schistosoma*, and more commonly against other cosmopolitan parasites such as nematodes, *Babesia*, *Giardia*, and *Coccidia* [33]. In the study conducted by of Said *et al.* (2012), the results showed that curcumin nanoparticles synthesized by ionic crosslinking of curcumin solution at the dose of 450 mg for 8 d significantly reduced the number of *Giardia* cysts (54.6%) in the stool and trophozoites (51.7%) in intestinal sections of the rats with giardiasis [16].

Citrullus colocynthis nanoparticles

Citrullus colocynthis is an herbaceous plant from the Cucurbitaceae family that contains pectin and alkaloids such as Elatylene A and Elatyrin B with various pharmacological properties such as anti-diabetic, anti-cancer, anti-inflammatory, anti-oxidant, and antimicrobial properties [34, 35]. Recently, Al-Ardi *et al.* (2020) demonstrated that the oral administration of *C. colocynthis* nanoparticles at the dose of 20 µg for 8 d significantly reduced the mean number of *G. lamblia* trophozoites by 93.2% in Swiss Albino mice with giardiasis [18].

Inorganic nanoparticles

Gold

Gold is one of the vital elements which is broadly used in various medical fields such as biochemistry, microbiology, immunology, and cytology. Gold nanoparticles have many applications in medicine, including biosensors, clinical chemistry, immunoassays, genomics, photothermolysis of cancer cell. They also have other effects such as analgesic, anti-angiogenesis, anti-HIV virus, and anti-parasites, including *Plasmodium* spp., *Giardia* spp., *Leishmania* spp., etc. [17, 18, 36, 3].

In the study conducted by Bavand *et al.* (2014), gold NPs were used at the dose of 0.05, 0.1, 0.3 mg/ml for 5, 15, 30, 60, and 180 min against *G. lamblia* cysts. Their results showed that gold NPs at the concentration of 0.3 mg/ml in 180 min were able to kill 96% of cysts [17]. In addition, the study conducted by Al-Ardi (2020) demonstrated that oral administration of gold nanoparticles at the dose of 20 µg for 8 d significantly reduced the mean number of *G. lamblia* trophozoites by 93.2% in Swiss Albino mice with giardiasis [18].

Silver

Silver nanoparticles are one of the unique materials that have special physical and chemical properties such as resistance to oxidation and high thermal conductivity and are used in various fields such as industry, health, and medicine. Various pharmacological properties, including anti-inflammatory, anti-cancer, antioxidant, anti-angiogenic, and antimicrobial activities, have been attributed to silver nanoparticles. Regarding the antimicrobial effects of silver nanoparticles, previous reviews have represented the antimicrobial effects of these nanoparticles on a wide range of microbial pathogens such as *Escherichia coli*, *Candida* species, and HIV virus and parasites such as *Leishmania* spp. and *G. lamblia* [21, 38].

In the study conducted by Idan and Ardalan (2020) on BALB/c mice with giardiasis, it has been proven that use of silver nanoparticles at the dose of 100 µg/g reduced 83.30 and 66.6% of *Giardia* cysts after 72 and 24 h, respectively. In another study conducted by Said *et al.* (2012), it was proven that silver nanoparticles obtained by green synthesis at the dose of 50 µg for 8 d can reduce 72.7% of *G. lamblia* cysts in the mice with giardiasis [16].

Selenium

Selenium is a semi-solid metal that is classified as a trace element and was discovered as a byproduct of sulfuric acid synthesis. Many studies have studied the properties of this element, including anti-diabetic, anti-cancer, antioxidant, and anti-inflammatory [39]. In addition, this element has various antimicrobial activities such as anti-viral, antibacterial, as well as anti-parasites effects against as

Entamoeba histolytica and *Giardia* spp. [20, 39]. In the study conducted by Malekifard and Tavassoli (2020), the results showed that selenium nanoparticles at various concentrations, particularly at the dose of 0.6 mg/ml after 10, 15, 30, 60, and 180 min incubation, killed 100% of *G. deudenalis* cysts *in vitro* [20].

Copper oxide

Copper oxide nanoparticles are the semiconductor compound with many applications such as in industrial catalyst, gas sensors, electronic materials, biomedicines, and environmental remediation [40, 41]. In addition, it has been used as antimicrobial agents against some microbial pathogens such as *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Entamoeba histolytica*, and *Cryptosporidium parvum*, *G. deudenalis* [20, 42]. Considering the anti-parasitic effects of copper oxide nanoparticles, Malekifard and Tavvasoli (2020) found these nanoparticles at various concentrations, particularly at the dose of 0.6 mg/ml after 180 min incubation, killed 97% of *G. deudenalis* cysts *in vitro* [20].

Zinc oxide

Zinc is one of the trace elements with different compounds which have various pharmacological properties [43]. Zinc oxide (ZnO) nanoparticles are a favorable compound for use in biomedical field, particularly given their anticancer and antimicrobial activities [44]. Considering antimicrobial effects of ZnO NPs, previous studies have demonstrated these nanoparticles have potent antimicrobial properties against some of the pathogenic microbial strains such as *Streptococcus pneumonia*, *Bacillus subtilis*, *Eimeria papillata*, *Leishmania* spp., and *Giardia* spp. [45]. In the study by Reham *et al.* (2019), it was found that the use of ZnO nanoparticles at the dose of 10 mg/kg and for the period of 7 d alone could eliminate 93.7% of *Giardia* cysts in mice; if combined with metronidazole, it had 100% lethality [22].

CONCLUSION

The results of this review showed the high efficacy of a wide range of organic and non-organic NPs against giardiasis, indicating that nanoparticles could be considered as an alternative and complementary resource for treating giardiasis since they had no significant toxicity. In addition, we found no resistance formation against nanoparticles for giardiasis. However, more studies are required to elucidate this conclusion, especially in clinical systems.

AVAILABILITY OF DATA AND MATERIALS

All data generated or analyzed during this study are included in this published article.

FUNDING

Nil

AUTHORS CONTRIBUTIONS

All authors have contributed equally.

CONFLICTS OF INTERESTS

Declared none

REFERENCES

1. Lujan HD. Giardia and giardiasis. Medicina (B Aires) 2006;66:70-4.
2. Adam RD. Biology of giardia lamblia. Clin Microbiol Rev 2001;14:447-75.
3. Obulesu G, Ar H. A study of stool samples from hiv positive and hiv negative at Andhra Pradesh. Asian J Pharm Clin Res 2018;1:394-7.
4. Hooshyar H, Rostamkhani P, Arbabi M, Delavari M. Giardia lamblia infection: review of current diagnostic strategies. Gastroenterol Hepatol Bed Bench 2019;12:3-12.
5. Escobedo AA, Cimerman S. Giardiasis: a pharmacotherapy review. Expert Opin Pharmacother 2007;8:1885-902.
6. Tian HF, Chen B, Wen JF. Giardiasis, drug resistance, and new target discovery. Infect Disord Drug Targets 2010;10:295-302.

7. Lalle M, Hanevik K. Treatment-refractory giardiasis: challenges and solutions. *Infect Drug Resist* 2018;11:1921-33.
8. Kingsley JD, Dou H, Morehead J, Rabinow B, Gendelman HE, Destache CJ. Nanotechnology: a focus on nanoparticles as a drug delivery system. *J Neuroimmune Pharmacol* 2006;1:340-50.
9. Nafari A, Cheraghypour K, Sepahvand M, Shahrokhi G, Gabal E, Mahmoudvand H. Nanoparticles: new agents toward treatment of leishmaniasis. *Parasite Epidemiol Control* 2020;10:e00156.
10. Albalawi AE, Alanazi AD, Baharvand P, Sepahvand M, Mahmoudvand H. High potency of organic and inorganic nanoparticles to treat cystic echinococcosis: an evidence-based review. *Nanomaterials* 2020;10:2538.
11. Albalawi AE, Khalaf AK, Alyousif MS, Alanazi AD, Baharvand P, Shakibaie M, et al. Fe3O4@ piroctone olamine magnetic nanoparticles: synthesize and therapeutic potential in cutaneous leishmaniasis. *Biomed Pharmacother* 2021;139:111566.
12. Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med* 2009;151:264-9.
13. Yarahmadi M, Fakhar M, Ebrahimzadeh MA, Chabra A, Rahimi-esboei B. The anti-giardial effectiveness of fungal and commercial chitosan against *Giardia intestinalis* cysts *in vitro*. *J Parasit Dis* 2016;40:75-80.
14. Chabra A, Rahimi Esboei B, Habibi E, Monadi T, Azadbakht M, Elmi T, et al. Effects of some natural products from fungal and herbal sources on *Giardia lamblia* *in vivo*. *Parasitology* 2019;146:1188-98.
15. El-Gendy AM, Mohammed MA, Ghallab MM, Abdel Aziz MO, Ibrahim SM. Therapeutic effect of chitosan nanoparticles and metronidazole in the treatment of experimentally giardiasis infected hamsters. *Iranian J Parasitol* 2021;16:32-42.
16. Said DE, ElSamad LM, Gohar YM. Validity of silver, chitosan, and curcumin nanoparticles as anti-Giardia agents. *Parasitol Res* 2012;111:545-54.
17. Bavand Z, Gholami S, Honari S, Rahimi Esboei B, Torabi N, Borabadi H. Effect of gold nanoparticles on *Giardia Lamblia* cyst stage *in vitro*. *Arak Med Univ J* 2014;16:27-37.
18. Al-Ardi MH. The uses of gold nanoparticles and *Citrullus colocynthis* L. nanoparticles against *Giardia lamblia* *in vivo*. *Clin Epidemiol Glob Heal* 2020;8:1282-6.
19. Elmi T, Rahimi Esboei B, Sadeghi F, Zamani Z, Didehdar M, Fakhar M, et al. *In vitro* antiprotozoal effects of nano-chitosan on *Plasmodium falciparum*, *Giardia lamblia* and *Trichomonas vaginalis*. *Acta Parasitol* 2021;66:39-52.
20. Malekifard F, Tavassoli KV M. *In vitro* assessment antiparasitic effect of selenium and copper nanoparticles on giardia deodenalis cyst. *Iran Soc Parasitol* 2020;15:411-7.
21. Idan EM, Ardalan NM. Introducing silver nanoparticles as anti-giardial in experimentally infected mice. *Ther Versus Toxicity* 2020;11:701-8.
22. Reham M Brakat, Shaimaa A Sharaf EL-Deen HIAE. Zinc oxide nanoparticles kill giardia and protect against intestinal damage. *Egypt J Med Microbiol* 2019;28:95-103.
23. AlMohammed HI, Khudair Khalaf A, E Albalawi A, Alanazi AD, Baharvand P, Moghaddam A, et al. Chitosan-based nanomaterials as valuable sources of anti-leishmanial agents: a systematic review. *Nanomaterials* 2021;11:689.
24. Patel DP, Singh S. Chitosan: a multifaceted polymer. *Int J Curr Pharm Res* 2015;7:21-8.
25. Muxika A, Etxabide A, Uranga J, Guerrero P, de la Caba K. Chitosan as a bioactive polymer: processing, properties and applications. *Int J Biol Macromol* 2017;105:1358-68.
26. Wang W, Meng Q, Li Q, Liu J, Zhou M, Jin Z, et al. Chitosan derivatives and their application in biomedicine. *Int J Mol Sci* 2020;21:487.
27. Ahmed TA, Aljaeid BM. Preparation, characterization, and potential application of chitosan, chitosan derivatives, and chitosan metal nanoparticles in pharmaceutical drug delivery. *Drug Des Dev Ther* 2016;10:483-507.
28. Cheraghypour K, Masoori L, Ezzatkah F, Salimikia I, Amiri S, Makenali AS, et al. Effect of chitosan on toxoplasma gondii infection: a systematic review. *Parasite Epidemiol Control* 2020;11:e00189.
29. Rize BR, Younes NN, Rasool K, Nasrallah GK. Synthesis, bioapplications, and toxicity evaluation of chitosan-based nanoparticles. *Int J Mol Sci* 2019;20:5776.
30. Guan G, Azad AK, Lin Y, Kim SW, Tian Y, Liu G, et al. Biological effects and applications of chitosan and chitoooligosaccharides. *Front Physiol* 2019;10:516.
31. Rozman NAS, Tong WY, Leong CR, Tan WN, Hasanolbasori MA, Abdullah SZ. Potential antimicrobial applications of chitosan nanoparticles (ChNP). *J Microbiol Biotechnol* 2019;29:1009-13.
32. Krishnamurthy G, Roy D, Kumar J. Curcumin, a natural golden drug and its anticancer aspects from synthesis to delivery: a review. *Int J Appl Pharm* 2020;7:70-84.
33. Cheraghypour K, Ezatpour B, Masoori L, Marzban A, Sepahvand A, Rouzbahani AK, et al. Anti-candida activity of curcumin: a systematic review. *Curr Drug Discovery Technol* 2021;18:379-90.
34. Satyavani K, Gurudeeban S, Ramanathan T, Balasubramanian T. Biomedical potential of silver nanoparticles synthesized from calli cells of *Citrullus colocynthis* (L.) schrad. *J Nanobiotechnol* 2011;9:43.
35. Hussain AI, Rathore HA, Sattar MZ, Chatha SA, Sarker SD, Gilani AH. *Citrullus colocynthis* (L.) schrad (bitter apple fruit): a review of its phytochemistry, pharmacology, traditional uses and nutritional potential. *J Ethnopharmacol* 2014;15:54-66.
36. Dykman LA, Khebtsov NG. Gold nanoparticles in biology and medicine: recent advances and prospects. *Acta Nat* 2011;3:34-55.
37. Das M, Shim KH, An SSA, Yi DK. Review on gold nanoparticles and their applications. *Toxicol Environ Health Sci* 2011;3:193-205.
38. Zhang XF, Liu ZG, Shen W, Gurunathan S. Silver nanoparticles: Synthesis, characterization, properties, applications, and therapeutic approaches. *Int J Mol Sci* 2016;17:1534.
39. Rayman MP. Selenium and human health. *Lancet* 2012;379:1256-68.
40. Ezzatkah F, Khalaf AK, Mahmoudvand H. Copper nanoparticles: biosynthesis, characterization, and protoscolicidal effects alone and combined with albendazole against hydatid cyst protoscoleces. *Biomed Pharmacother* 2021;136:111257.
41. Albalawi AE, Abdel Shafy S, Khudair Khalaf A, Alanazi AD, Baharvand P, Ebrahimi K, et al. Therapeutic potential of green synthesized copper nanoparticles alone or combined with meglumine antimoniate (glucantime®) in cutaneous leishmaniasis. *Nanomaterials* 2021;11:891.
42. Saadatmand M, Al-Awsi GR, Alanazi AD, Sepahvand A, Shakibaie M, Shojaei S, et al. Green synthesis of zinc nanoparticles using *lavandula angustifolia vera*. extract by microwave method and its prophylactic effects on *Toxoplasma gondii* infection. *Saudi J Biol Sci* 2021. <https://doi.org/10.1016/j.sjbs.2021.07.007>
43. Roohani N, Hurrell R, Kelishadi R, Schulin R. Zinc and its importance for human health: an integrative review. *J Res Med Sci* 2013;18:144.
44. Sirelkhatim A, Mahmud S, Seeni A, Kaus NH, Ann LC, Bakhori SK, et al. Review on zinc oxide nanoparticles: antibacterial activity and toxicity mechanism. *Nano-micro Lett* 2015;7:219-42.
45. Nadhman A, Nazir S, Khan MI, Ayub A, Muhammad B, Khan M, et al. Visible-light-responsive ZnCuO nanoparticles: benign photodynamic killers of infectious protozoans. *Int J Nanomed* 2015;10:6891-903.